Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Am J Obstet Gynecol ; 2024 Jul 03.
Article in English | MEDLINE | ID: mdl-38969201

ABSTRACT

BACKGROUND: Although the levonorgestrel 52 mg intrauterine device is locally active and has low systemic hormone exposure, hormonal intrauterine device users sometimes report hormone-related side effects. OBJECTIVE: Evaluate hormone-related adverse event rates among all participants and compare these among those who used combined hormonal or no hormonal contraception in the month before enrollment. STUDY DESIGN: A total of 1714 women aged 16-45 years old received a levonorgestrel 52 mg intrauterine device in a multicenter phase 3 trial to evaluate contraceptive efficacy and safety for up to 10 years. This analysis evaluated a subset of participants who used combined hormonal or no hormonal contraception in the month prior to device placement. We assessed all non-expulsion, non-bleeding-related events with ≥1% incidence at 180 days with a plan to include weight increase regardless of incidence; we excluded events considered non-hormonal. We computed 180-day side effect frequency rates based on the number of days a side effect was reported during the study period. We created a multivariable model for side effect incidence at 180 days based on age, race, ethnicity, body mass index at enrollment, parity, and contraception use in the month before enrollment. For those side effects with a p-value <0.2 on univariate comparison between combined-hormonal and no-hormonal contraception users, we secondarily evaluated 360-day event rates. RESULTS: Overall, 644 participants used combined hormonal contraception (primarily oral [n=499, 77.5%]) and 855 used no hormonal method before IUD placement. Individual side effect rates over the first 180 days did not differ between prior combined-hormonal and no-hormonal contraception users except for acne (84 [13.0%] versus 73 [8.5%], respectively), p=0.006, OR 1.61 (95% CI 1.15-2.24). However, this association was weaker after adjustment for age, race, ethnicity, obesity status, and parity (aOR 1.40, 95% CI 0.99-1.98) At 360 days, prior combined hormonal contraception users were more likely to report acne (101 [15.7%] vs. 91 [10.6%], respectively, p=0.005) and orgasm/libido problems (20 [3.1%] vs. 12 [1.4%], respectively, p=0.03). Over the first 180 days, all side effects other than acne were reported in less than 3% of days; acne was reported an average of 13 days (7.4%) per prior combined hormonal contraception user and 9 days (5.0%) per prior non-hormonal contraception user (p<0.0001). Discontinuation for evaluated side effects occurred in 83 (5.5%) participants with no difference between those who used combined hormonal (36 [5.6%]) or no hormonal contraception (47 [5.5%]), p=1.0) before study entry. CONCLUSIONS: Using combined hormonal contraception prior to levonorgestrel 52 mg intrauterine device placement is only weakly associated with reporting hormonally related side effects like acne. Only a small percentage of levonorgestrel 52 mg intrauterine device users experienced potentially hormone-related side effects during the initial 6 months of use that resulted in discontinuation.

2.
Contraception ; 124: 110058, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37164148

ABSTRACT

OBJECTIVES: Health care providers, including anesthesia providers, hold varied personal views on abortion, which influences their involvement in multidisciplinary abortion care. We aimed to explore Southeastern US anesthesia providers' perspectives on abortion provision and factors impacting their decision to provide anesthesia for hospital-based induced abortion. STUDY DESIGN: We conducted in-depth, individual interviews with currently practicing anesthesia providers in the Southeastern United States. We recruited participants from regional anesthesiology conferences and via snowball sampling. A semistructured interview guide explored domains of obstetric experiences, standardized abortion cases, and personal abortion attitudes. We coded data iteratively and analyzed data thematically using inductive approaches with qualitative software. RESULTS: Fifteen participants completed interviews, at which point thematic saturation occurred. Participants represented a range of provider type and prior abortion experience. Participants weighed "personal and professional viewpoints" in considering their willingness to provide anesthesia care for hospital-based abortion. Many participants who personally disagreed with some abortion indications were still willing to provide anesthesia in those cases, some implicitly naming principles of medical ethics to justify differing professional and personal opinions. Participants also considered their "role in abortion decision-making": all participants reported that the abortion decision belongs to the patient or their obstetrician and not the anesthesia provider. CONCLUSIONS: Southeastern US anesthesia providers are influenced by multiple factors when considering their participation in hospital-based abortion care. Acknowledging differences in professional and personal viewpoints and identifying roles in abortion decision-making might be important to engaging anesthesia providers in abortion care, especially for high-risk medical or fetal indications. IMPLICATIONS: This original, qualitative study identified several inductive themes that characterize how Southeastern US anesthesia providers formulate their level of participation in hospital-based abortion care. Acknowledging differences in professional and personal viewpoints and identifying roles in abortion decision-making might facilitate interdisciplinary abortion care, especially for high-risk medical or fetal indications.


Subject(s)
Abortion, Induced , Anesthesia , Anesthesiology , Pregnancy , Female , Humans , Attitude of Health Personnel , Qualitative Research
3.
J Vasc Interv Radiol ; 33(4): 427-435.e4, 2022 04.
Article in English | MEDLINE | ID: mdl-34915166

ABSTRACT

PURPOSE: To identify differences in mortality or length of hospital stay for mothers treated with uterine artery embolization (UAE) or hysterectomy for severe postpartum hemorrhage (PPH), as well as to analyze whether geographic or clinical determinants affected the type of therapy received. MATERIALS AND METHODS: This National Inpatient Sample study from 2005 to 2017 included all patients with live-birth deliveries. Severe PPH was defined as PPH that required transfusion, hysterectomy, or UAE. Propensity score weighting-adjusted demographic, maternal, and delivery risk factors were used to assess mortality and prolonged hospital stay. RESULTS: Of 9.8 million identified live births, PPH occurred in 31.0 per 1,000 cases. The most common intervention for PPH was transfusion (116.4 per 1,000 cases of PPH). Hysterectomy was used more frequently than UAE (20.4 vs 12.9 per 1,000 cases). The following factors predicted that hysterectomy would be used more commonly than UAE: previous cesarean delivery, breech fetal position, placenta previa, transient hypertension during pregnancy without pre-eclampsia, pre-existing hypertension without pre-eclampsia, pre-existing hypertension with pre-eclampsia, unspecified maternal hypertension, and gestational diabetes (all P < .001). Delivery risk factors associated with greater utilization of hysterectomy over UAE included postterm pregnancy, premature rupture of membranes, cervical laceration, forceps vaginal delivery, and shock (all P < .001). There was no difference in mortality between hysterectomy and UAE. After balancing demographic, maternal, and delivery risk factors, the odds of prolonged hospital stay were 0.38 times lower with UAE than hysterectomy (P < .001). CONCLUSIONS: Despite similar mortality and shorter hospital stays, UAE is used far less than hysterectomy in the management of severe PPH.


Subject(s)
Postpartum Hemorrhage , Uterine Artery Embolization , Female , Humans , Hysterectomy/adverse effects , Inpatients , Postpartum Hemorrhage/etiology , Postpartum Hemorrhage/therapy , Pregnancy , Retrospective Studies , Uterine Artery Embolization/adverse effects
4.
Am J Obstet Gynecol ; 223(6): 884.e1-884.e10, 2020 12.
Article in English | MEDLINE | ID: mdl-32534843

ABSTRACT

BACKGROUND: Pain management approaches during uterine aspiration vary, which include local anesthetic, oral analgesics, moderate sedation, deep sedation, or a combination of approaches. For local anesthetic approaches specifically, we continue to have suboptimal pain control. Gabapentin as an adjunct to pain management has proven to be beneficial in gynecologic surgery. We sought to evaluate the impact of gabapentin on perioperative pain during surgical management of first-trimester abortion or early pregnancy loss with uterine aspiration under local anesthesia. OBJECTIVE: We hypothesized that adding gabapentin to local anesthesia will reduce perioperative and postoperative pain associated with uterine aspiration. Secondary outcomes included tolerability of gabapentin and postoperative pain, nausea, vomiting, and anxiety. STUDY DESIGN: We conducted a randomized double-blinded placebo-controlled trial of gabapentin 600 mg given 1 to 2 hours preoperatively among subjects receiving a first-trimester uterine aspiration under paracervical block in an outpatient ambulatory surgery center. There were 111 subjects randomized. The primary outcome was pain at time of uterine aspiration as measured on a 100-mm visual analog scale. Secondary outcomes included pain at other perioperative time points. To assess changes in pain measures, an intention to treat mixed effects model was fit with treatment groups (gabapentin vs control) as a between-subjects factor and time point as a within-subjects factor plus their interaction term. Because of a non-normal distribution of pain scores, the area under the curve was calculated for secondary outcomes with comparison of groups utilizing Mann-Whitney U tests. RESULTS: Among the 111 randomized, most subjects were Black or African American (69.4%), mean age was 26 years (±5.5), and mean gestational age was 61.3 days (standard deviation, 14.10). Mean pain scores at time of uterine aspiration were 66.77 (gabapentin) vs 71.06 (placebo), with a mean difference of -3.38 (P=.51). There were no significant changes in pain score preoperatively or intraoperatively. Subjects who received gabapentin had significantly lower levels of pain at 10 minutes after surgery (mean difference [standard error (SE)]=-13.0 [-5.0]; P=.01) and 30 minutes after surgery (mean difference [SE]=-10.8 [-5.1]; P=.03) compared with subjects who received placebo. Median nausea scores and incidence of emesis pre- and postoperatively did not differ between groups. Similarly, anxiety scores did not differ between groups, before or after the procedure. At 10 and 30 minutes after the procedure, most participants reported no side effects or mild side effects, and this did not differ between groups. CONCLUSION: Preoperative gabapentin did not reduce pain during uterine aspiration. However, it did reduce postoperative pain, which may prove to be a desired attribute of its use, particularly in cases where postoperative pain may be a greater challenge.


Subject(s)
Analgesics/therapeutic use , Anesthesia, Local/methods , Anesthesia, Obstetrical/methods , Gabapentin/therapeutic use , Pain, Postoperative/prevention & control , Pain, Procedural/prevention & control , Vacuum Curettage/methods , Abortion, Induced/methods , Abortion, Spontaneous/surgery , Adult , Double-Blind Method , Female , Humans , Pain Management , Pain, Postoperative/drug therapy , Pain, Procedural/drug therapy , Pregnancy , Pregnancy Trimester, First , Young Adult
5.
Menopause ; 25(7): 817-827, 2018 07.
Article in English | MEDLINE | ID: mdl-29462093

ABSTRACT

Family planning represents a key component of reproductive health care. Accordingly, the provision of contraception must span the reproductive age spectrum, including perimenopause. The risk of pregnancy is decreased, but not trivial, among women over 40 years of age. Evidence-based guidelines for contraceptive use can assist clinicians in counseling their patients in this population. Intrauterine contraception is one of the most effective methods and is safe to use in midlife women with few exceptions. Progestin-only contraception is another safe option for most midlife women because it is not associated with an increased risk of cardiovascular complications. Combined (estrogen-containing) contraception can be safely used by midlife women who do not have cardiovascular risk factors. Unique noncontraceptive benefits for this population include: improvement in abnormal uterine bleeding, decreased hot flashes, and decreased cancer risk. Finally, guidelines state that contraception can be used by midlife women without medical contraindications until the age of menopause, at which time they may consider transition to systemic hormone therapy.


Subject(s)
Contraception/methods , Family Planning Services/standards , Perimenopause , Reproductive Health/standards , Adult , Female , Humans , Middle Aged
6.
J Rural Health ; 34(2): 122-131, 2018 03.
Article in English | MEDLINE | ID: mdl-28731204

ABSTRACT

PURPOSE: To evaluate the difference in tubal ligation use between rural and urban counties in the state of Georgia, USA. METHODS: The study population included 2,160 women aged 22-45. All participants completed a detailed interview on their reproductive histories. County of residence was categorized using the National Center for Health Statistics Urban-Rural Classification Scheme. We estimated the association between urbanization of county of residence and tubal ligation using Cox regression. Among women with a tubal ligation, we examined factors associated with prior contraception use and the desire for more children. FINDINGS: After adjustment for covariates, women residing in rural counties had twice the incidence rate of tubal ligation compared with women in large metropolitan counties (adjusted hazard ratio [aHR] = 2.0, 95% CI = 1.4-2.9) and were on average 3 years younger at the time of the procedure. No differences were observed between small metropolitan and large metropolitan counties (aHR = 1.1, CI = 0.9-1.5). Our data suggest that women from large metropolitan counties are slightly more likely than women from rural counties to use hormonal contraception or long-acting reversible contraception prior to tubal ligation and to desire more children after tubal ligation. CONCLUSIONS: Women from rural counties are more likely to undergo a tubal ligation than their urban counterparts. Our results suggest that circumstances regarding opting for tubal ligation may differ between urban and rural areas, and recommendations of alternative contraceptive options may need to be tailored differently for rural areas.


Subject(s)
Rural Population/statistics & numerical data , Sterilization, Tubal/statistics & numerical data , Urban Population/statistics & numerical data , Adult , Female , Georgia , Humans , Incidence , Middle Aged , Proportional Hazards Models
7.
Obstet Gynecol ; 129(6): 1137, 2017 06.
Article in English | MEDLINE | ID: mdl-28538478
8.
Obstet Gynecol ; 129(1): 3-9, 2017 01.
Article in English | MEDLINE | ID: mdl-27926643

ABSTRACT

OBJECTIVE: To understand the most important steps required to implement immediate postpartum long-acting reversible contraception (LARC) programs in different Georgia hospitals and the barriers to implementing such a program. METHODS: This was a qualitative study. We interviewed 32 key personnel from 10 Georgia hospitals working to establish immediate postpartum LARC programs. Data were analyzed using directed qualitative content analysis principles. We used the Stages of Implementation to organize participant-identified key steps for immediate postpartum LARC into an implementation guide. We compared this guide to hospitals' implementation experiences. RESULTS: At the completion of the study, LARC was available for immediate postpartum placement at 7 of 10 study hospitals. Participants identified common themes for the implementation experience: team member identification and ongoing communication, payer preparedness challenges, interdependent department-specific tasks, and piloting with continuing improvements. Participants expressed a need for anticipatory guidance throughout the process. Key first steps to immediate postpartum LARC program implementation were identifying project champions, creating an implementation team that included all relevant departments, obtaining financial reassurance, and ensuring hospital administration awareness of the project. Potential barriers included lack of knowledge about immediate postpartum LARC, financial concerns, and competing clinical and administrative priorities. Hospitals that were successful at implementing immediate postpartum LARC programs did so by prioritizing clear communication and multidisciplinary teamwork. Although the implementation guide reflects a comprehensive assessment of the steps to implementing immediate postpartum LARC programs, not all hospitals required every step to succeed. CONCLUSION: Hospital teams report that implementing immediate postpartum LARC programs involves multiple departments and a number of important steps to consider. A stage-based approach to implementation, and a standardized guide detailing these steps, may provide the necessary structure for the complex process of implementing immediate postpartum LARC programs in the hospital setting.


Subject(s)
Contraception , Health Plan Implementation/organization & administration , Hospitals , Physician's Role , Program Development/methods , Communication , Contraception/economics , Contraceptive Agents, Female/administration & dosage , Drug Implants , Electronic Health Records , Female , Financial Management, Hospital , Georgia , Humans , Interviews as Topic , Intrauterine Devices , Nurse's Role , Pharmacy Service, Hospital , Postpartum Period , Reimbursement Mechanisms
9.
Dig Dis Sci ; 62(1): 54-63, 2017 01.
Article in English | MEDLINE | ID: mdl-27885460

ABSTRACT

Gastroenterologists are in a unique position to assist women with chronic gastrointestinal disorders in order to optimize their health prior to pregnancy. Women, whether with chronic conditions or not, and their infants are more likely to be healthy when pregnancies are planned. Achieving a planned pregnancy at the ideal time or preventing pregnancy altogether requires the use of appropriate contraceptives. There is a broad range of contraceptives available to women in the USA, and the majority of women with digestive diseases will be candidates for all effective methods. Guidance from the Centers for Disease Control and Prevention aids clinicians in prescribing appropriate contraceptives to women with medical disorders. This review will focus on contraception for women with inflammatory bowel disease and chronic liver disease, including liver transplant.


Subject(s)
Contraception/methods , Inflammatory Bowel Diseases , Liver Cirrhosis , Colitis, Ulcerative , Contraceptive Agents, Female/therapeutic use , Contraceptives, Oral, Combined/therapeutic use , Contraceptives, Oral, Hormonal/therapeutic use , Crohn Disease , Digestive System Diseases , Disease Management , Female , Humans , Intrauterine Devices, Medicated , Levonorgestrel/therapeutic use , Liver Transplantation
10.
Menopause ; 23(1): 111-3, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26671193

ABSTRACT

Despite a decline in fertility, women of older reproductive age who do not desire pregnancy should use contraception until menopause. Unintended pregnancy can be disruptive at any age, but in older women, pregnancy is associated with higher rates of adverse health outcomes for the mother and the fetus because of advanced age and comorbid medical conditions (e.g., hypertension or diabetes). Therefore, providing appropriate contraceptive care to women of older reproductive age is critical.


Subject(s)
Contraception/standards , Perimenopause , Contraception/methods , Contraceptives, Oral, Hormonal/standards , Contraindications , Female , Humans , Intrauterine Devices/standards , Middle Aged , Practice Guidelines as Topic , Pregnancy
11.
Am J Obstet Gynecol ; 212(6): 740-6, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25511241

ABSTRACT

Among the most prevalent and disabling chronic diseases affecting reproductive-aged women worldwide, depression and anxiety can contribute to adverse reproductive health outcomes, including an increased risk of unintended pregnancy and its health and social consequences. For women with these common mental health conditions who want to avoid an unintended pregnancy, effective contraception can be an important strategy to maintain and even improve health and well-being. Reproductive health clinicians play a critical role in providing and managing contraception to help women with mental health considerations achieve their desired fertility. In this commentary, we review the literature on relationships between mental health and contraception and describe considerations for the clinical management of contraception among women with depression and anxiety. We discuss issues related to contraceptive method effectiveness and adherence concerns, mental health-specific contraceptive method safety and drug interaction considerations, and clinical counseling and management strategies. Given important gaps in current scientific knowledge of mental health and contraception, we highlight areas for future research.


Subject(s)
Anxiety , Contraception , Contraceptive Agents, Female , Depression , Mental Health , Anxiety/epidemiology , Depression/epidemiology , Female , Humans
13.
Infect Dis Obstet Gynecol ; 2012: 107878, 2012.
Article in English | MEDLINE | ID: mdl-22761541

ABSTRACT

BACKGROUND: The aim of this study was to determine current contraceptive use, contraceptive desires and knowledge, future fertility desires, and sterilization regret in a cohort of HIV-positive women. STUDY DESIGN: 127 HIV-positive women receiving care at an urban infectious disease clinic completed a survey addressing their contraceptive and reproductive histories as well as their future contraceptive and fertility desires. RESULTS: The most common forms of contraception used were sterilization (44.4%) and condoms (41.3%). Less than 1% used a long-term reversible method of contraception (LARC) despite these being the methods that best fit their desired attributes of a contraceptive method. Overall, 29.4% desired future fertility. Only 50.6% of those sexually active had spoken with a provider within the last year regarding their contraceptive plans. There was a high degree of sterilization regret (36.4%), and 18.2% of sterilized women desired future fertility. Multivariate analysis found women in a monogamous relationship had a statistically increased rate of regret compared to women who were not sexually active (OR 13.8, 95% CI 1.6-119, P = 0.17). CONCLUSION: Given the diversity in contraceptive and fertility desires, coupled with a higher rate of sterilization regret than is seen in the general population, integration of comprehensive family planning services into HIV care via increased contraceptive education and access is imperative.


Subject(s)
Contraception Behavior/psychology , Fertility , HIV Infections/psychology , Health Knowledge, Attitudes, Practice , Cohort Studies , Contraceptive Agents, Female , Contraceptive Devices/statistics & numerical data , Female , HIV Infections/prevention & control , Health Services Needs and Demand , Humans , Multivariate Analysis , Sterilization, Tubal/psychology , Sterilization, Tubal/statistics & numerical data , United States
14.
Contraception ; 76(4): 314-8, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17900444

ABSTRACT

BACKGROUND: Vaginal microbicides represent an important emerging class of antiinfectives. To guide research and development, we conducted a survey to determine interest in desired qualities of and intended use of microbicides within the current milieu of contraceptive options. STUDY DESIGN: Women completed an anonymous survey while waiting for health care clinic appointments in Portland, OR, and Atlanta, GA, and in one public area (Atlanta). RESULTS: Four hundred one women completed the survey. Subjects had a mean age of 25.6 (SD=7.4), parity of 1.5 (SD=1.6) and 47.7% were non-Caucasian. Respondents showed moderate interest in noncontraceptive anti-HIV gel-based microbicides (mean, 53.8; SD, 39.6; n=362) and significantly stronger interest in contraceptive anti-HIV microbicides (mean, 89.4 mm; SD, 20.7; n=363; p<.001). The qualities of HIV, pregnancy and sexually transmitted infection (STI) prevention were the highest priorities of the largest percentage (40%) of respondents. Half (49.6%) of respondents reported they would use another form of protection in conjunction with a contraceptive anti-HIV microbicide. CONCLUSIONS: A diverse sample of women reported substantial interest in vaginal microbicides capable of preventing HIV and pregnancy, and a smaller high-risk subgroup was interested in noncontraceptive anti-HIV microbicides. Most women would prefer a product capable of preventing HIV, pregnancy and STIs. Almost half of respondents would use vaginal microbicides as part of a dual method.


Subject(s)
Anti-HIV Agents/therapeutic use , Anti-Infective Agents, Local/therapeutic use , Patient Satisfaction , Spermatocidal Agents/therapeutic use , Vaginal Creams, Foams, and Jellies/therapeutic use , Adolescent , Adult , Data Collection , Drug Combinations , Female , HIV Infections/prevention & control , Humans , Sexually Transmitted Diseases/prevention & control
15.
Contraception ; 73(6): 609-12, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16730493

ABSTRACT

OBJECTIVE: The purpose of this study is to assess the long-term knowledge retention and learning skills among third year medical students who had been taught about contraception 1 year previously. STUDY DESIGN: In 2002-2003, 150 third-year medical students were taught contraception in either an interactive or a standard format. Students completed exams at 2-4 weeks and 1 year after sessions. Scores were compared to determine long-term knowledge retention (paired t test). At 1 year, students assessed the long-term impact of the contraceptive lecture (visual analogue scales). RESULTS: This study had a 40% response rate (60/150, interactive 34/77, standard 26/73). Overall, test scores decreased three points (8.6%), with an average test score of 22/35 (p<.01) at 1 year. Follow-up test scores were equivalent between lecture groups (p=.64). Use of a contraceptive resource tended to be higher in the interactive group (50% vs. 27%, p=.08). Students requested that more time be devoted to teaching contraception (78%). CONCLUSION: Both teaching formats are equivalent in their impact on long-term knowledge retention.


Subject(s)
Contraception/methods , Curriculum , Learning , Reproductive Medicine/education , Adult , Female , Humans , Retention, Psychology , Teaching/methods
16.
Am J Obstet Gynecol ; 191(5): 1788-92, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15547565

ABSTRACT

OBJECTIVE: Our purpose was to determine whether an interactive medical student contraceptive teaching session results in improved knowledge gain or satisfaction when compared with a standard, didactic lecture. STUDY DESIGN: An interactive lecture was compared with a standard lecture among third-year medical students at Oregon Health and Science University School of Medicine and Medical College of Georgia. Knowledge gain was assessed by comparing correct responses to a posttest with the students' own responses to the same questions given as a pretest before the lecture. Satisfaction with the lecture was assessed on a visual analog scale. Scores and satisfaction ratings were compared within and between lecture groups. RESULTS: A total of 150 students participated. There was a significant increase in test scores within both the interactive and standard groups ( P < .0001 for both groups). The change in scores did not differ significantly between the groups ( P = .087). Although overall satisfaction was significantly greater with the standard lecture ( P = .004), it was high with both lectures. CONCLUSION: Knowledge gain with the interactive lecture was equivalent to that with the standard lecture. Satisfaction with both learning formats was high.


Subject(s)
Contraception , Reproductive Medicine/education , Teaching , Adult , Cohort Studies , Female , Georgia , Hospitals, University , Humans , Male , Oregon , Prospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...